Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baughman, R. P.
Right arrow Articles by Kaufman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baughman, R. P.
Right arrow Articles by Kaufman, A.
(Chest. 2005;128:1062-1047.)
© 2005 American College of Chest Physicians

Etanercept for Refractory Ocular Sarcoidosis*

Results of a Double-Blind Randomized Trial

Robert P. Baughman, MD, FCCP; Elyse E. Lower, MD; Deborah A. Bradley, MD; Lawrence A. Raymond, MD and Adam Kaufman, MD

*From the Departments of Internal Medicine (Drs. Baughman, Lower, and Bradley) and Ophthalmology (Drs. Raymond and Kaufman), University of Cincinnati Medical Center, Cincinnati, OH.

Correspondence to: Robert P. Baughman MD, 1001 Holmes, Eden Ave, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565; e-mail address bob.baughman{at}uc.edu

Purpose: Study a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis.

Subjects and methods: Eighteen patients with ocular sarcoidosis and ongoing inflammation in the eyes. All patients had received at least 6 months of therapy with methotrexate and were currently receiving corticosteroids. Patients were randomized to receive either etanercept, 25 mg subcutaneously twice a week, or placebo in a double-blind randomized trial. Treatment for ocular inflammation with systemic and local corticosteroids at the beginning and end of 6 months of treatment was noted. All patients underwent an ocular examination at the beginning and the end of the study by one ophthalmologist who was unaware of what treatment the patient was receiving.

Results: Three of the patients treated with etanercept and one treated with placebo were being treated with lower doses of corticosteroids by the end of the study. However, three of the etanercept patients and one of the placebo patients required larger doses of corticosteroids by the end of the study. The ophthalmology global assessment improved for two of the etanercept-treated patients and three of the placebo-treated patients.

Conclusion: For most patients, therapy with etanercept was not associated with a significant improvement in their chronic ocular disease.

Key Words: etanercept • methotrexate • ocular sarcoidosis • tumor necrosis factor






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.